This message is from NPR sponsor Microsoft.

How can smart leaders use AI to transform their business?

On the WorkLab Podcast for Microsoft, they go behind the scenes with experts to find out what you need to know.

That's WorkLab, No Spaces, and you can find it wherever you get your

podcasts. You're listening to Shortwave from NPR.

Hey Shortwavers, Emily Kwong here with NPR Science reporter Will Stone,

who's been reporting on the use of psychedelics for therapy.

And just a heads up, we do mention suicide and suicidal thoughts in this story. Well, welcome. Let's get

into this reporting. What do you got? Hey Emily, I'm here to talk about MDMA,

that's the chemical found in ecstasies sometimes called Molly.

Researchers have been studying MDMA as a potential therapy for post-traumatic stress

disorder, PTSD.

And in August, the FDA is expected to decide whether it can be used as a treatment

option outside of clinical research meaning it would be available to many more

people. This would be a big development. It would. FDA approval would be

actually an enormous milestone for the movement to bring psychodelics into the

mainstream of mental health care. Wow. But recent allegations have sparked controversy over the results from one of the clinical trials,

which could upset the final stretch in the drugs path to market. So today on the show, how the government is moving toward a decision about

psychedelics and mental health care.

And how a recent report questions the data the FDA is using to make that decision.

You are listening to Short Wise, the app that makes

managing your money in different currencies easy. With WISE you can send and spend money

...